Haematopoietic alterations in neonates with congenital diaphragmatic hernia receiving extracorporeal membrane oxygenation support

Abstract

Background

Extracorporeal membrane oxygenation procedure (ECMO) has been established in the therapy of respiratory insufficient infants with congenital diaphragmatic hernia. In congenital diaphragmatic hernia newborns, a delay in transfer to an ECMO centre is associated with a sharp increase in mortality. Predictive factors for ECMO support are urgently needed. We evaluated the routine parameters of the first blood withdrawal after birth in congenital diaphragmatic hernia infants, hypothesizing that early signs in bone marrow affecting haematology parameters for early regulation of potentially post birth hypoxia are predictive factors for ECMO support.

Materials and methods

In 44 patients born with congenital diaphragmatic hernia, differential blood cell count from the first blood withdrawal after birth was examined. Descriptive statistics included median, 95% confidence intervals, minimum and maximum differentiating ECMO/early mortality vs. no ECMO. Odds ratios with CI were calculated by binary logistic regression analysis. Best predictive markers were further checked in combination with the liver-up situation in two factorial regression models.

Results

In our cohort, the survival rate was 77.3% (34/44). While 18 neonates received ECMO support, 26 experienced no ECMO during hospital stay. Odds ratio calculations showed that risk for ECMO support increases with augmenting leukocytes, erythrocytes, haemoglobin, haematocrit, mean cell volume and absolute immature granulocytes. Further, the risk advanced in line with the severity of congenital diaphragmatic hernia assessed by prenatal ultrasound.

Conclusions

We conclude that these parameters are associated with disease severity in congenital diaphragmatic hernia newborns and may be considered potentially predictive biomarkers for the necessity of ECMO support.

Keywords

Congenital diaphragmatic hernia WBC ECMO

Introduction

Congenital diaphragmatic hernia (CDH) is a rare disease with an incidence of 1 to 2500–3000 in live births. Its clinical presentation varies widely and is associated with high mortality and long-term morbidity.¹ During development, an orifice remains in the diaphragm, which ultimately leads to organ herniation into the thorax, hypoplasia of the pulmonary vasculature and the airway system and pulmonary hypertension with insufficient oxygenation after birth. Additional malformations are often involved.² Although much effort has been spent to improve therapeutic options, mortality rates remain high.³ For several years, extracorporeal membrane oxygenation procedure (ECMO) has been established in the therapy of respiratory insufficient infants with CDH.⁴ Despite being controversially discussed, it is a widely used procedure.⁵ Since a delayed transfer (i.e. > 24 h after birth) to an ECMO centre is associated with a sharp increase in mortality in CDH newborns, predictive factors for ECMO support are urgently needed.⁶ In infants with CDH, a lower observed-to-expected lung-to-head ratio (o/e LHR) and an intrathoracic liver position (liver-up) are associated with worse outcome, and risk stratification is possible in line with this information.^7,8 Although many studies are investigating the pathomechanisms, little is known regarding changes in haematopoiesis.⁹ Following admission to a hospital setting, the complete blood cell count is always determined in CDH newborns. While there are continuous improvements in the analysis technologies, complete blood cell count should be evaluated as a predictive factor for ECMO support in CDH infants. Blood cell count parameters are of outstanding importance in a variety of childhood diseases. Immature platelet fraction (IPF) is a parameter that differentiates causes for thrombocytopenia.¹⁰ Cremer et al. have shown its value in sepsis diagnosis in neonates.¹¹ Immature granulocytes (IG) seem to be a predictive factor in neonatal sepsis.¹² Elevated nucleated red blood cells (NRBC) are predictive of mortality in very low birth weight infants.¹³ Foetal erythropoiesis is regulated by complex mechanisms due to physiologically low oxygen partial pressure in utero in contrast to erythropoiesis after birth.¹⁴ While the role of regulation in bone marrow activity for all cell lines has not yet been evaluated in CDH infants, data from an animal model indicate that erythropoietin (EPO) as a progenitor to red cell differentiation is impaired in CDH.¹⁵

The aim of the present study was to assess blood cell count values early after birth as part of routine analysis for predicting ECMO in these patients.

Patients and methods

Setting

This is a single centre retrospective observational study performed at the central laboratory and the Department of Neonatology and Pediatric Critical Care Medicine of the University Clinics Bonn, Germany. The department of neonatology is a large level III perinatal centre with approximately 600 admissions/year (approx. 80 very low birth weight infants, 20–30 CDH infants, approx. 15 neonatal ECMOs).

Patients

The collective included data from 44 patients born with CDH from February 2014 to April 2016. One child died immediately after birth, and data were not included for further analysis. Data were collected from the central laboratory information system (SWISSLAB II, Roche, Berlin, Germany), from the neonatal information system (Neodat, Tubingen, Germany) and the internal CDH database. Criteria for ECMO were based on current recommendations of the CDH-Euro Consortium: preductal oxygen saturation <85% or postductal saturation <70%, OI ≥40 consistently present, increased PaCO₂>70 mmHg with a pH <7.15, a peak inspiratory pressure ≥28 cm H₂O or mean airway pressure ≥17 cm H₂O or persistent systemic hypotension (mean arterial pressure <40 mmHg).¹⁶

Methods

Venous EDTA whole blood samples were examined. In all samples, analysis was performed within 15 min of arrival at the central laboratory. We analysed values from the first blood withdrawal after birth. Values at the central laboratory were measured with Sysmex XN1000™ (Sysmex, Norderstedt, Germany). Hb concentration was photometrically measured with the sodium lauryl sulphate (SLS) haemoglobin method. Erythrocytes were measured with impedance technique. Thrombocytes and IPF were measured by fluorescent staining. Haematocrit and mean cell volume (MCV) were determined with summarizing impulse heights; mean corpuscular haemoglobin and mean corpuscular haemoglobin concentration were computed parameters. Lymphocytes, monocytes, neutrophil granulocytes, eosinophil granulocytes and IG were measured with fluorescence flow cytometry in the WDF channel, while basophil granulocytes were measured in the WNR channel. All methods are part of routine methods at the central laboratory (accredited according to DIN EN ISO 15189:2014) and are performed in line with legal requirements (RiliBÄK, Guideline of the German Medical Association) with stipulated internal and external quality controls.

Statistics

Data were statistically analysed using IBM SPSS® Statistics, Version 20 (Ehningen, Germany) and MedCalc® (Ostend, Belgium). P < 0.05 was considered statistically significant. Variables were described with median value (95% confidence interval [CI]), minimum and maximum differentiating ECMO/early mortality vs. no ECMO. Values were obtained during the first blood withdrawal. Next, odds ratios with CI and P-values were calculated for a set of potentially predictive markers by binary logistic regression analysis. Best predictive markers were further checked in combination with the liver-up situation in two factorial regression models and odds ratios with CI and P-values were obtained. Box-plots were generated with median, interquartile ranges, minimum and maximum. Receiver operating characteristics (ROC) curves and areas under the curve (AUC) were calculated.

Ethics

In article six of the German Data Protection Act (https://recht.nrw.de/lmi/owa/br_text_anzeigen?v_id= 10000000000000000495#), it is stipulated that the physician may use existing patient data for retrospective analyses without explicitly asking for the consent of patients. The study design is consistent with the Declaration of Helsinki. According to information obtained from the Institutional Review Board (Ethikkommission an der Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn, Chairman K. Racké, MD, PhD, Professor, University Bonn), retrospective analysis of data obtained during routine treatment and diagnosis does not require consultation by the ethics committee according to article 15 of the German medical professional code.

Results

In our cohort, the survival rate was 77.3% (34/44), survival-to-discharge was 77.3% and the median age at discharge in survivors was 45 days (range: 13–255 days). No fatalities occurred after discharge and all patients attended regular follow-up visits in our outpatient clinic. The median age at the latest follow-up was 3.4 years (range: 2.1–4.7 years). While 18 neonates received ECMO support, 26 required no ECMO during hospital stay. One patient died immediately after birth; four children with early mortality due to contraindication to ECMO despite fulfilling ECMO criteria were included in the ECMO group. Male to female ratio was 3.2:1. Ten infants in the ECMO/early mortality group died (10/18, 55.5%) and 27 infants (61.4%) suffered from CDH with liver-up condition. In all patients, blood for CBC analysis was withdrawn after insertion of an umbilical catheter 20 and 45 min after birth. The median age of initiating ECMO support was 9.6 h (IQR 7.1–19.4 h). Patient characteristics, including gestational age, birth weight, lung-to-head ratio, duration of ventilation, hospital stay, score for neonatal acute physiology-II (SNAP-II) and analytes for patients with or without ECMO therapy are presented in Table 1. Odds ratios, 95% CI and P-values for potentially predictive markers for ECMO therapy are presented in Table 2.

Table 1.

Descriptive statistics from first blood withdrawal of children born with CDH treated with or without ECMO therapy.

	No ECMO therapy					ECMO therapy/early mortality
	n	Median	95% CI	Minimum	Maximum	n	Median	95% CI	Minimum	Maximum
Gestational age (days)	26	262.5	255.0–267.0	198.0	284.0	18	265.0	249.2–269.0	232.0	278.0
o/e LHR (28 SSW)	24	40.0	38.0–45.1	18.0	90.8	16	34.5	29.7–38.4	21.0	66.0
Birth weight	25	3000.0	2705.9–3289.7	1470.0	4070.0	18	2840.0	2519.9–3348.1	2200.0	4460.0
SNAP-II	23	14.0	5.0–23.7	0.0	61.0	16	32.0	23.0–47.0	16.0	66.0
Duration ventilation	23	8.0	6.7–10.2	1.0	29.9	12	22.0	14.5–28.6	11.1	49.5
Duration O2 delivery	21	7.9	6.0–14.0	0.6	54.6	12	56.6	23.3–79.5	11.6	172.5
ERY (T/L)	26	4.4	4.2–4.5	3.2	5.9	18	4.7	4.3 – 5.0	3.9	5.5
LEUK (G/L)	26	12.5	11.0–14.2	6.7	27.5	18	18.4	14.6–20.6	8.6	29.2
IG (%)	15	1.8	1.4–3.7	0.5	6.0	4	2.6		0.9	3.0
IGAB (G/L)	15	0.3	0.173–0.5	0.04	1.1	4	0.5		0.08	0.7
ERY (T/L)	26	4.4	4.2–4.5	3.2	5.9	18	4.7	4.3–5.0	3.9	5.5
HB (g/dL)	26	15.4	15.0–16.6	11.4	20.2	18	17.4	16.4–18.3	14.1	20.4
HK (%)	26	44.0	42.5–48.0	32.0	55.0	18	50.0	46.4–52.2	42.0	90.0
MCH (pg)	26	36.0	35.0–37.0	33.0	41.0	18	37.0	36.0–38.6	35.0	40.0
MCHC (g/dL)	26	35.0	35.0–36.0	33.0	37.0	18	35.0	34.4–36.0	32.0	36.0
MCV (fL)	26	101.5	98.5–104.0	91.0	116.0	18	108.0	104.4–109.0	98.0	115.0
NRBCAB (G/L)	26	0.4	0.2–0.8	0.04	6.4	17	0.6	0.4–1.1	0.1	5.0
RDW (%)	26	16.2	15.7–16.7	14.2	19.1	17	16.7	16.0–16.9	14.9	19.5
RETAB (G/L)	26	194.2	167.7–207.1	112.5	294.6	17	189.9	181.542–204.9	160.3	370.3
RET (%)	26	4.5	3.9–4.9	2.5	6.3	17	4.2	3.9–4.6	3.4	6.7
THROF (G/L)	24	222.0	173.7–262.1	108.0	386.0	17	244.0	203.2–308.5	192.0	406.0
MPV (fL)	25	10.4	9.9–11.2	8.9	13.0	17	10.6	10.0–11.3	9.0	12.2
IPF (%)	24	3.8	2.1–4.5	0.8	10.0	17	2.9	2.1–4.1	1.4	8.4
IPFAB (G/L)	24	7.6	5.3–9.0	2.2	31.7	17	8.0	5.6–10.7	3.5	21.1

Note: Total numbers, median + 95% confidence interval (CI) and minimum and maximum are presented for children born with CDH treated with or without ECMO therapy (ECMO therapy group includes early mortality cases).

o/e LHR: observed-to-expected lung-to-head ratio; SNAP-II: score for neonatal acute physiology-II; LEUK: leukocytes; IG: immature granulocytes; AB: absolute; ERY: erythrocytes; HB: haemoglobin; HK: haematocrit; MCH: mean corpuscular haemoglobin; MCHC: mean corpuscular haemoglobin concentration; MCV: mean cell volume; NRBC: nucleated red blood cells; RDW: red cell distribution; RET: reticulocytes; THROF: thrombocytes; MPV: mean platelet volume; IPF: immature platelet fraction.

Table 2.

Odds ratios, 95% confidence intervals (CI) and P-values for predictive markers for ECMO therapy.

Analyte	Odds ratio	95% CI	P
Gestational age	1.0	1.0–1.04	0.902
Birth weight	1.0	0.999–1.001	0.669
Liver-up	5.0	1.2–21.5	0.031
SNAP-II	1.1	1.0–1.1	0.007
Duration ventilation	1.2	1.1–1.4	0.004
Duration 02 delivery	1.1	1.0–1.16	0.009
Leukocytes	1.2	1.1–1.4	0.008
IG %	0.9	0.4–1.9	0.730
IG AB	1.7	0.04–71.7	0.787
Erythrocytes	2.0	0.6–6.8	0.260
Haemoglobin	1.4	1.0–2.0	0.045
Haematocrit	1.1	1.0–1.3	0.045
MCV	1.2	1.0–1.3	0.014
MCH	1.4	1.0–1.9	0.069
MCHC	0.8	0.5–1.3	0.388
RDW	1.2	0.7–1.9	0.482
NRBC AB	1.2	0.7–1.9	0.469
RET %	1.1	0.6–2.1	0.786
RET AB	1.0	1.0–1.0	0.450
THROF	1.0	1.0–1.0	0.177
MPV	1.1	0.6–2.2	0.701
IPF %	1.0	0.7–1.3	0.845
IPF AB	1.0	1.0–1.2	0.465

Note: Presented are odds ratios, 95% CI and p-values for differential blood parameters and patients characteristics at first withdrawal after birth regarding ECMO therapy.

SNAP-II: score for neonatal acute physiology-II; IG: immature granulocytes; AB: absolute; ERY: erythrocytes; HB: haemoglobin; HK: haematocrit; MCH: mean corpuscular haemoglobin; MCHC: mean corpuscular haemoglobin concentration; MCV: mean cell volume; NRBC: nucleated red blood cells; RDW: red cell distribution; RET: reticulocytes; THROF: thrombocytes; MPV: mean platelet volume; IPF: immature platelet fraction.

Value distributions of analytes and outcome parameters in ECMO vs. no ECMO groups are displayed in boxplots (see Supplemental Figure 1).

Supplemental Figure 2 shows ROC curves and areas under the curve for the analysed parameters (see Supplemental Figure 2). Best predictive markers were further analysed in combination with the liver-up situation in two factorial regression models. Results for odds ratios with 95% confidence intervals and P-values are presented in Table 3.

Table 3.

Odds ratios, 95% confidence intervals (CI) and P-values assessed in combination with the liver-up situation in two factorial regression models for best markers as predictive factors for ECMO therapy.

Analyte- Pairwise comparison with Liver-up	Odds ratio	95% CI	P
Liver-up	6.14	1.1–34.23	0.039
Leukocytes	1.24	1.1–1.45	0.009
Liver-up	2.76	0.23–33.76	0.427
IG AB	2.01	0.5–88.5	0.718
Liver-up	4.61	1.01–20.17	0.042
Erythrocytes	1.63	0.5–5.7	0.445
Liver-up	3.71	0.81–17.05	0.092
Haemoglobin	1.3	0.91–1.87	0.150
Liver-up	3.34	0.71–15.7	0.126
Haematocrit	1.1	0.97–1.25	0.141
Liver-up	2.75	0.55–13.82	0.219
MCV	1.13	0.99–1.29	0.079

Note: Presented are odds ratios, 95% CI and p-values for best predictive markers at first blood withdrawal after birth regarding ECMO therapy analysed in combination with liver-up.

IG: immature granulocytes; AB: absolute; MCV: mean cell volume.

Discussion

Management of CDH newborns remains a great challenge today with high morbidity and mortality.¹⁷ Schaible et al. reported a sharp increase in mortality in CDH newborns following delayed (i.e. > 24 h after birth) transfer to an ECMO centre.⁶ Additionally, newborns surviving after ECMO support might demonstrate neurocognitive impairment as a crucial side-effect.¹⁸ Therefore, factors predicting the need for ECMO support are paramount in these patients. Although ECMO treatment outcome in neonates is generally satisfactory, ECMO support in CDH patients can cause disorders, such as problems in hearing and vision, impaired neurocognitive development, concentration problems, etc.¹⁹ We assessed the values of blood count analytes immediately (ca. 30 min) after birth for predicting ECMO in children born with CDH. In order to establish a new predictor for outcome, it is important that measurement of CBC is not to close to the predicted event. In our study, the median time of approximately 9 h from blood sampling to initiation of ECMO support, represents long enough duration to plan ECMO cannulation. Odds ratio calculations showed in combination with liver-up that risk for ECMO support grows with increased levels of leukocytes. Erythrocytes, haemoglobin, MCV and absolute IG in combination with liver-up situation show an elevated risk for ECMO therapy. Further, the risk increased in line with severity of CDH as assessed by prenatal ultrasound (i.e. o/e LHR, liver-up). We conclude that these parameters are associated with disease severity in CDH newborns and may be considered potentially predictive biomarkers for the necessity of ECMO support. ECMO support is a therapeutic option in critically respiratory insufficient neonates.⁵ Our results indicate that these parameters are not only predictive for the necessity of ECMO support but may also predict different outcome parameters during the hospital treatment (e.g. duration of ventilation, oxygen dependency). Haemoglobin is the most important component of the erythrocyte, which is linked to the oxygen transport capacity. Reticulocytes can be seen as an indicator for effectiveness of erythropoiesis.²⁰ To our knowledge, changes in blood cell lines have not been previously investigated in CDH newborns.

Evidence from a CDH animal model shows that EPO synthesis is suppressed in CDH rats and that it is associated with more severe CDH.¹⁵ However, based on these findings, we would expect to observe a reduced amount of haemoglobin. Erythroid cells mature with the help of EPO, but EPO does not affect differentiation and survival of erythrocytes.²¹ Additionally, it is well described that erythropoiesis is stimulated not only by EPO but also by several other factors, including interleukins IL-3, IL-6 and IL-9.^22,23 Previous studies suggest an increased expression of several proinflammatory cytokines, including IL-6, in more severely affected CDH newborns.²⁴ Therefore, increased IL-6 expression during foetal life could be responsible for the significant alterations in the blood cell lines observed in our study. Future studies need to investigate a potential interaction between inflammation and erythropoiesis in CDH newborns. However, EPO measurement is expensive and requires a high sample volume for measurement making it less attractive as a biomarker candidate in CDH newborn research.

Theoretically, the reported changes in haematopoietic cells might result from severe hypoxia due to CDH-associated lung hypoplasia, which may stimulate EPO-mediated erythropoiesis. However, in the majority of patients, blood was drawn for analysis within the first 30 min after delivery, allowing only a limited time period for potential hypoxia to affect blood count parameters. Furthermore, our cohort consisted of patients with prenatally diagnosed CDH, and in this setting, all infants received optimal care within a standardized protocol, including immediate intubation and ventilation with 100% oxygen as recommended.¹⁶ Therefore, a substantial number of patients may not have experienced profound hypoxia during initial resuscitation. Additionally, delayed cord clamping was not performed in any patient during the study period and volume supplementation during early postnatal resuscitation was similar between groups (data not shown).

In a recent study, the commercially widely available high-sensitivity troponin T and N-terminal pro-brain natriuretic peptides were not predictive for subsequent ECMO support in CDH newborns.²⁵ Beside biomarkers, foetal lung size and intrathoracic liver herniation can be used as prenatal predictive factors for ECMO support.²⁶ Additionally, approaches using echocardiographic assessment or calculation of SNAP II have been reported.^27,28 We focused on haematopoietic cells with their indices for several reasons: our reported analytes can be measured from a very small sample volume, the technique is inexpensive, with a round-the-clock availability in every hospital setting. Since blood sampling from infants could lead to relevant anaemia, a further advantage was that no extra blood had to be taken, and analysis was carried out rapidly as no centrifugation step is necessary for haematology analysis. In contrast to previous studies, IPF measuring was performed with improved fluorescence technique for the haematology analyser.^10,11,29 All analytes underlie internal and external quality control schemes in our accredited laboratory. In previous studies, standardization and comparability of the analysed materials were rarely provided.²⁵ Our results for SNAP-II as a predictive factor for ECMO support are in line with previously reported results.²⁹

Limitations of the study

Routine diagnostic was carried out in the context of first treatment of our patients and took place on average within 20 min during routine conditions after placement of umbilical vessel catheter. We did not correct the P-value for multiple testing in our study. Therefore, the chosen significance level of P < 0.05 incorporates the likelihood of false-positive associations given the number of significance tests performed and should be considered to be explorative. An additional limitation is the retrospective character of our study, and all findings need to be confirmed with a prospective design.

Conclusion

We evaluated routine parameters of the first blood withdrawal after birth in CDH infants hypothesizing that early signs in bone marrow affecting haematology parameters of children with CDH for early regulation of potentially post birth hypoxia are predictive factors for ECMO support. We found that increased leukocytes, erythrocytes, haemoglobin, HK, MCV, absolute IG and liver-up condition are predictive factors for ECMO support. Our results need confirmation by a larger observational study.

Supplemental Material

Supplemental Figure legends - Supplemental material for Haematopoietic alterations in neonates with congenital diaphragmatic hernia receiving extracorporeal membrane oxygenation support

Supplemental material, Supplemental Figure legends for Haematopoietic alterations in neonates with congenital diaphragmatic hernia receiving extracorporeal membrane oxygenation support by Ramona C Dolscheid-Pommerich, Alexander Kreuzer, Ingo Graeff, Birgit Stoffel-Wagner, Andreas Mueller and Florian Kipfmueller in Annals of Clinical Biochemistry

Supplemental Material

Supplemental Figure1 - Supplemental material for Haematopoietic alterations in neonates with congenital diaphragmatic hernia receiving extracorporeal membrane oxygenation support

Supplemental material, Supplemental Figure1 for Haematopoietic alterations in neonates with congenital diaphragmatic hernia receiving extracorporeal membrane oxygenation support by Ramona C Dolscheid-Pommerich, Alexander Kreuzer, Ingo Graeff, Birgit Stoffel-Wagner, Andreas Mueller and Florian Kipfmueller in Annals of Clinical Biochemistry

Supplemental Material

Supplemental Figure2 - Supplemental material for Haematopoietic alterations in neonates with congenital diaphragmatic hernia receiving extracorporeal membrane oxygenation support

Supplemental material, Supplemental Figure2 for Haematopoietic alterations in neonates with congenital diaphragmatic hernia receiving extracorporeal membrane oxygenation support by Ramona C Dolscheid-Pommerich, Alexander Kreuzer, Ingo Graeff, Birgit Stoffel-Wagner, Andreas Mueller and Florian Kipfmueller in Annals of Clinical Biochemistry

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval

Not applicable. The study design is consistent with the Declaration of Helsinki.

Guarantor

FK.

Contributorship

RCDP, BSW, AM and FK researched literature and conceived the study. RCDP, AK, IG, BSW, AM and FK were involved in protocol development, gaining ethical approval, patient data recruitment and data analysis. RCDP, AK, IG, BSW, AM and FK wrote the article. All authors reviewed and edited the article and approved the final version of the article.

References

Morini

Lally

et al . The Congenital Diaphragmatic Hernia Study Group Registry. Eur J Pediatr Surg 2015; 25: 488–496.

Tovar

JA.

Congenital diaphragmatic hernia. Orphanet J Rare Dis 2012; 7: 1.

Stege

Fenton

Jaffray

Nihilism in the 1990s: the true mortality of congenital diaphragmatic hernia. Pediatrics 2003; 112: 532–535.

Stolar

Snedecor

Bartlett

RH.

Extracorporeal membrane oxygenation and neonatal respiratory failure: experience from the extracorporeal life support organization. J Pediatr Surg 1991; 26: 563–571.

Hung

Huang

Mazloum

et al . Extracorporeal membrane oxygenation for neonatal congenital diaphragmatic hernia: the initial single-center experience in Taiwan. J Formos Med Assoc 2017; 116: 333–339.

Schaible

Hermle

Loersch

et al . A 20-year experience on neonatal extracorporeal membrane oxygenation in a referral center. Intensive Care Med 2010; 36: 1229–1234.

Albanese

Lopoo

Goldstein

et al . Fetal liver position and perinatal outcome for congenital diaphragmatic hernia. Prenat Diagn 1998; 18: 1138–1142.

Tsukimori

Masumoto

Morokuma

et al . The lung-to-thorax transverse area ratio at term and near term correlates with survival in isolated congenital diaphragmatic hernia. J Ultrasound Med 2008; 27: 707–713.

Fauza

Tannuri

Ayoub

et al . Surgically produced congenital diaphragmatic hernia in fetal rabbits. J Pediatr Surg 1994; 29: 882–886.

10.

Cremer

Weimann

Schmalisch

et al . Immature platelet values indicate impaired megakaryopoietic activity in neonatal early-onset thrombocytopenia. Thromb Haemost 2010; 103: 1016–1021.

11.

Cremer

Weimann

Szekessy

et al . Low immature platelet fraction suggests decreased megakaryopoiesis in neonates with sepsis or necrotizing enterocolitis. J Perinatol 2013; 33: 622–626.

12.

Cimenti

Erwa

Herkner

et al . The predictive value of immature granulocyte count and immature myeloid information in the diagnosis of neonatal sepsis. Clin Chem Lab Med 2012; 50: 1429–1432.

13.

Cremer

Roll

Gräf

et al . Nucleated red blood cells as marker for an increased risk of unfavorable outcome and mortality in very low birth weight infants. Early Hum Dev 2015; 91: 559–563.

14.

Kuruvilla

Widness

Nalbant

et al . A method to evaluate fetal erythropoiesis from postnatal survival of fetal RBCs. AAPS J 2015; 17: 1246–1254.

15.

Takayasu

Hagiwara

Masumoto

Suppressed erythropoietin expression in a nitrofen-induced congenital diaphragmatic hernia. Pediatr Pulmonol 2017; 52: 606–615.

16.

Snoek

Reiss

Greenough

et al . CDH EURO Consortium. Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: The CDH EURO Consortium Consensus – 2015 Update. Neonatology 2016; 110: 66–74.

17.

Kalanj

Salevic

Rsovac

et al . Congenital diaphragmatic hernia – a Belgrade single center experience. J Perinat Med 2016; 44: 913–918.

18.

Mok

Lee

Cheifetz

IM.

Neonatal extracorporeal membrane oxygenation: update on management strategies and long-term outcomes. Adv Neonatal Care 2016; 16: 26–36.

19.

Engle

West

Hocutt

et al . Adult outcomes after newborn respiratory failure treated with extracorporeal membrane oxygenation. Pediatr Crit Care Med 2017; 18: 73–79.

20.

Geaghan

SM.

Hematologic values and appearances in the healthy fetus, neonate, and child. Clin Lab Med 1999; 19: 1–37.

21.

Brandt

Koury

MJ.

Regulation of LMO₂ mRNA and protein expression in erythroid differentiation. Haematologica 2009; 94: 447–448. Review.

22.

Gardner

Liechty

KW.

Effects of interleukin-6 on fetal hematopoietic progenitors. Blood 1990; 75: 2150.

23.

Holbrook

ST.

Effect of interleukin-9 on clonogenic maturation and cell-cycle status of fetal and adult hematopoietic progenitors. Blood 1991; 77: 2129.

24.

Schaible

Veit

Tautz

et al . Serum cytokine levels in neonates with congenital diaphragmatic hernia. Klin Padiatr 2011; 223: 414–418.

25.

Snoek

Kraemer

Ten Kate

et al . High-sensitivity troponin T and N-terminal pro-brain natriuretic peptide in prediction of outcome in congenital diaphragmatic hernia: results from a multicenter, randomized controlled trial. J Pediatr 2016; 173: 245–249.

26.

Russo

Eastwood

Keijzer

et al . Lung size and liver herniation predict the need for extra corporeal membrane oxygenation but not pulmonary hypertension in isolated congenital diaphragmatic hernia: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2017; 49: 704–771. Review.

27.

Snoek

Capolupo

Morini

et al . Congenital Diaphragmatic Hernia EURO Consortium: Score for Neonatal Acute Physiology-II predicts outcome in congenital diaphragmatic hernia patients. Pediatr Crit Care Med 2016; 17: 540–546.

28.

Patel

Kipfmueller

Cardiac dysfunction in congenital diaphragmatic hernia: pathophysiology, clinical assessment, and management. Semin Pediatr Surg 2017; 26: 154–158.

29.

Briggs

Longair

Kumar

et al . Performance evaluation of the Sysmex haematology XN modular system. J Clin Pathol 2012; 65: 1024–1030.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.08 MB

0.10 MB

0.16 MB